Durable protection from Herpes Simplex Virus-2 transmission following intravaginal application of siRNAs targeting both a viral and host gene.
about
Nanostructures for the Inhibition of Viral InfectionsLipid nanoparticles as carriers for RNAi against viral infections: current status and future perspectivesKnocking down disease: a progress report on siRNA therapeuticsCurrent prospects for RNA interference-based therapiesProgress toward in vivo use of siRNAs-IISpray-dried powders enhance vaginal siRNA delivery by potentially modulating the mucus molecular sieve structureA rapid and sensitive method to detect siRNA-mediated mRNA cleavage in vivo using 5' RACE and a molecular beacon probeEmerging nanotechnology approaches for HIV/AIDS treatment and prevention.Nanoparticle-based drug delivery to the vagina: a review.A general RNA motif for cellular transfection.RNAi-based therapeutics-current status, challenges and prospectsInhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras.Fusing structure and function: a structural view of the herpesvirus entry machinery.Optimizing siRNA delivery to the genital mucosasiRNA-based topical microbicides targeting sexually transmitted infections.Pathogenesis of neonatal herpes simplex 2 disease in a mouse model is dependent on entry receptor expression and route of inoculation.Polymer nanoparticles encapsulating siRNA for treatment of HSV-2 genital infection.RNA interference for the treatment of papillomavirus disease.Increasing expression of microRNA 181 inhibits porcine reproductive and respiratory syndrome virus replication and has implications for controlling virus infection.Target delivery of small interfering RNAs with vitamin E-coupled nanoparticles for treating hepatitis CDurable knockdown and protection from HIV transmission in humanized mice treated with gel-formulated CD4 aptamer-siRNA chimerasNovel approaches in fighting herpes simplex virus infectionsSilencing sexually transmitted infections: topical siRNA-based interventions for the prevention of HIV and HSVLipidic systems for in vivo siRNA delivery.Chemical modification of siRNA.RNA interference-based therapeutics for human immunodeficiency virus HIV-1 treatment: synthetic siRNA or vector-based shRNA?Worldwide circulation of HSV-2 × HSV-1 recombinant strains.Special delivery: targeted therapy with small RNAs.Combinatorial prevention of HIV transmission in women: the case for a vaginal microbicide.Delivery systems and local administration routes for therapeutic siRNA.Protein and oligonucleotide delivery systems for vaginal microbicides against viral STIs.Immunological and hematological toxicities challenging clinical translation of nucleic acid-based therapeutics.Recombinant cell lines expressing shRNA targeting herpes simplex virus 2 VP16 inhibit virus replication.Intramuscular delivery of replication-defective herpes simplex virus gives antigen expression in muscle syncytia and improved protection against pathogenic HSV-2 strains.
P2860
Q26801513-E5D6D148-89BE-4048-B7F7-D29FE330F9EFQ26859021-E803AA45-8917-4D37-AFFD-E197167434EDQ28082939-AF6AAE51-F0AC-47F5-81FA-201D0CBE62CCQ28235733-A1104FAD-AB24-43FF-BEA9-4D7FBBAA9B21Q28255877-D9E8358B-4716-431A-BB19-B55158178303Q30403415-9149FD39-C839-40C5-B619-7C912EC5BA54Q33633775-49C57ADF-55A0-4749-BEFA-7FA74A20150CQ33819656-D6F62F13-DE0D-4B16-A778-59194772D464Q34079533-2EAF29A2-5DEB-48F0-BDD1-ED9A6255FB38Q34123063-F9D23558-F967-4C82-A860-F7A35D33D2CAQ34659612-E216ECFC-46D1-42DB-A96D-9D7038DFE515Q35015737-921C95D2-1915-4E9A-A830-7CAFB3814721Q35622700-9F445F63-7ECA-41DA-96B0-99D86C7D8936Q35766249-A3549AB5-6F90-4CD2-BF21-B6EAF0EC7725Q35766254-7361CEEC-F5C0-4FB0-8861-17E212BCEA11Q36506900-4CA4B3C0-81EB-4A12-91C4-29FA76DF67CAQ36528415-F7D05563-FA56-450F-A8EB-6559F11C1E90Q36540664-1BB3E15E-3DAA-4538-9470-5F616EB67A9FQ36559629-55FF0642-D55C-44BA-AB33-BBBD535C1C65Q36835758-063C33E9-B853-480B-82FF-2CFA0A47D43EQ36984469-DD41F57F-3196-41A3-9726-23B922881157Q37316071-E0F25FFB-85D7-492C-82A0-309662B8AB3BQ37553822-E23877E8-0867-4896-991A-6C5A3731A50BQ37598096-6648CAEF-0DBA-4483-8815-6D439D2910ABQ37655882-5C325A9D-E774-4EEC-B6D2-D58910108026Q37678411-C541ED56-C65D-4402-A934-ED18AF4E457AQ37695200-8410FE58-811B-4816-8299-45B6DDD55A1DQ37864924-22B3506C-E100-4621-B06C-A6FE27646116Q37907303-DD72A44E-F77C-4760-8CFF-C7A9BFE06F94Q38076344-61BEEFF5-7E67-433B-AF2A-86C5ECFD6A8CQ38260862-F33BA452-7818-4E02-B5CD-40A617A68DFEQ38504825-38ABA796-70A2-4E0F-835E-1DB5A96F6CC9Q39404887-4A87C98B-4753-4FD9-ACCB-584C3B1F8279Q45325692-448A4FB5-1EAC-43C4-B7E1-C3CFB7BFFC87
P2860
Durable protection from Herpes Simplex Virus-2 transmission following intravaginal application of siRNAs targeting both a viral and host gene.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Durable protection from Herpes ...... ng both a viral and host gene.
@en
Durable protection from Herpes ...... ng both a viral and host gene.
@nl
type
label
Durable protection from Herpes ...... ng both a viral and host gene.
@en
Durable protection from Herpes ...... ng both a viral and host gene.
@nl
prefLabel
Durable protection from Herpes ...... ng both a viral and host gene.
@en
Durable protection from Herpes ...... ng both a viral and host gene.
@nl
P2093
P2860
P1433
P1476
Durable protection from Herpes ...... ng both a viral and host gene.
@en
P2093
Ashish Lal
Deborah Palliser
Emre Basar
Francisco Navarro
Judy Lieberman
Muthiah Manoharan
Rajendra K Pandey
Sandra J Lee
P2860
P356
10.1016/J.CHOM.2008.12.003
P577
2009-01-01T00:00:00Z